New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era

References

• Ries LAG, Harkins D, Krapcho M et al.SEER Cancer Statistic Review, 1975–2003. National Cancer Institute, MD, USA (2006).
   Google Scholar
• Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur. J. Cancer29A, 2077–2079 (1993).
   PubMed Web of Science ®Google Scholar
• Midgley R, Kerr D. Colorectal cancer. Lancet353(9150), 391–399 (1999).
   PubMed Web of Science ®Google Scholar
• Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Collaborative Group. Br. Med. J.321(7260), 531–535 (2000).
   PubMed Web of Science ®Google Scholar
• O’Connell MJ. A Phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer63, S1026–S1030 (1989).
   PubMed Web of Science ®Google Scholar
• Petrelli N, Douglas HO Jr, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomised Phase III trial. Gastrointestinal Tumor Study Group. J. Clin. Oncol.7(10), 1419–1426 (1989).
   PubMed Web of Science ®Google Scholar
• The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol.22, 3766–3775 (2004).
   PubMed Web of Science ®Google Scholar
• Saltz L, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med.343(13), 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.18(6), 2938–2947 (2000).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet25, 1041–1047 (2000).
   Web of Science ®Google Scholar
• Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J. Clin. Oncol.24, 394–400 (2006).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22, 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Falcone A, Masi G, Brunetti G et al. The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs. the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer: results of a randomized Phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.). Proc. Am. Soc. Clin. Oncol.24, S18 (2006) (Abstract 3513).
   Google Scholar
• Hobday TJ, Cha SS, Sargent DJ et al. Long term survivors of metastatic colorectal cancer treated with chemotherapy only: a North Central Cancer Treatment Group review. Proc. Am. Soc. Clin. Oncol.21, (2002) (Abstract 693).
   Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285(21), 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer3, 401–410 (2003).
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo.Nature362(6423), 841–844 (1993).
   PubMed Web of Science ®Google Scholar
• Manley PW, Martin-Baron G, Schlaeppi J-M, Wood JM. Therapies directed at vascular endothelial growth factor. Expert Opin. Invest. Drugs11(12), 1715–1736 (2002).
   PubMed Web of Science ®Google Scholar
• Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer36(6), 748–753 (2000).
   PubMed Web of Science ®Google Scholar
• Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest.95(4), 1789–1797 (1995).
   PubMed Web of Science ®Google Scholar
• Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.Angiogenesis7(4), 335–345 (2004).
   PubMedGoogle Scholar
• Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intramural uptake of CPT-11. Br. J. Cancer88(12), 1979–1986 (2003).
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science307, 58–62 (2005).
   Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II randomised trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21(1), 60–65 (2003).
   PubMed Web of Science ®Google Scholar
• Kabbinabar F, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomised Phase II trial. J. Clin. Oncol.23(16), 3697–3705 (2005).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc. Am. Soc. Clin. Oncol.23, 16S (2005) (Abstract 2).
   Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized Phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19>–21 January 2007 (Abstract 238).
   Google Scholar
• Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyirimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: final analysis of the TREE-study. Proc. Am. Soc. Clin. Oncol.24, 18S (2006) (Abstract 3510).
   Google Scholar
• Hochster HS, Welles L, Hart L et al. Safety and efficacy of bevacizumab when added to oxaliplatin/fuoropyrimidine regimens as first-line treatment of colorectal cancer: TREE 1 & 2 Studies. Proc. Am. Soc. Clin. Oncol.23, 16S (2005) (Abstract 3515).
   Google Scholar
• Hedrick E, Kozloff M, Hainsworth J et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patient with metastasic colorectal cancer: update results from a large observational registry in the US (BRiTE). Proc. Am. Soc. Clin. Oncol.24, 18S (2006) (Abstract 3536).
   Google Scholar
• Berry SR, Cunningham D, Michael M et al. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for metastatic colorectal cancer: first B.E.A. Trial. Proc. Am. Soc. Clin. Oncol.24, 18S (2006) (Abstract 3534).
   Google Scholar
• Michael M, Van Cutsem E, Kretzschmar A et al. Feasibility of metastasectomy in patients treated with bevacizumab in first-line metastatic colorectal cancer: preliminary results from the First Beat study. Proc. Am. Soc. Clin. Oncol.24, 18S (2006) (Abstract 3523).
   Google Scholar
• Kretzschmar A, Cunningham D, Berry S et al. Feasibility of metastasectomy in patients treated with first-line bevacizumab for mCRC: preliminary results from the First BEAT study. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19–21 January 2007 (Abstract 343).
   Google Scholar
• Kesmodel SB, Ellis LM, Lin E et al. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab for colorectal cancer (CRC) liver metastases. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19–21 January 2007 (Abstract 234).
   Google Scholar
• Chen HX, Mooney M, Boron M et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J. Clin. Oncol.24(21), 3354–3360 (2006).
   PubMed Web of Science ®Google Scholar
• Jubb AM, Hurwitz HL, Bai W et al. Impact of vascular endothelial growth factor-A expression, thrombosporin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol.24, 217–227 (2006).
   PubMed Web of Science ®Google Scholar
• O’Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br. J. Cancer96(2), 189–195 (2007).
   PubMed Web of Science ®Google Scholar
• Schleucher N, Trarbach T, Junker U et al. Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.22, S14 (2004) (Abstract 3558).
   Google Scholar
• Tejpar S, Lin E, Bono P et al. A Phase Ib, open label, parallel design study of PTK787/ZK 222584 in combination with irinotecan in patients with metastatic colorectal cancer to investigate the interaction between the agents. Proc. Am. Soc. Clin. Oncol.23, 16S (2005) (Abstract 3594).
   Google Scholar
• Hecht JR, Trarbach T, Jaeger E et al. A randomized, double-blind, placebo-controlled, Phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM 1). Proc. Am. Soc. Clin. Oncol.23, 16S (2005) (Abstract 3).
   Google Scholar
• Koehne C, Bajetta E, Lin E et al. Results of an interim analysis of a multinational randomised, double blind, Phase III study in patients with previously treated metastatic colorectal cancer receiving FOLOFOX4 and PTK787/ZK222584 (PTK/ZK) or placebo (CONFIRM 2). Proc. Am. Soc. Clin. Oncol.24, 18S (2006) (Abstract 3508).
   Google Scholar
• Major P, Trarbach T, Lenz H et al. A meta-analyisis of two randomised, double-blind, placebo-controlled, Phase III studies in patients with matastatic colorectal cancer receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival in high LDH patients. Proc. Am. Soc. Clin. Oncol.24, 18S (2006) (Abstract 3529).
   Google Scholar
• Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res.65(10), 4389–4400 (2005).
   PubMed Web of Science ®Google Scholar
• Hemming AW, Davis NL, Kluffinger A et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J. Surg. Oncol.51(3), 147–152 (1992).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor positive tumors: a new paradigm for cancer therapy. Cancer94(5), 1593–1611 (2002).
   PubMed Web of Science ®Google Scholar
• Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res.1(11), 1311–1318 (1995).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Rubin M, Hochster H et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer that express the epidermal growth factor receptor. Proc. Am. Soc. Clin. Oncol.20, 3A (2001) (Abstract 7).
   Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J. Clin. Oncol.22(7), 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Wilke H, Glynne-Jones R, Thaler J et al. MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan. Proc. Am. Soc. Clin. Oncol.24, S18 (2006) (Abstract 3549).
   Google Scholar
• Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter Phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol.24(30), 4914–4921 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenberg AH, Loehrer PJ, Needle MN et al. Erbitux (IMC-C225) plus weekly irinotecan, fluorouracil, and leucovorin in colorectal cancer that express the epidermal growth factor receptor. Proc. Am. Soc. Clin. Oncol.21 (2002) (Abstract 536).
   Google Scholar
• Folprecht G, Lutz M, Schefski P et al. Cetuximab/irinotecan/high-dose 5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 22–24 January 2004 (Abstract 283).
   Google Scholar
• Rougier P, Raoul J-L, Van Laethem J-L et al. Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.22, 14S (2004) (Abstract 3513).
   Google Scholar
• Cervantes A, Tabernero J, Van Cutsem E et al. An international Phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil/folinic acid (FOLFOX4) in the first-line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor (EGFR). Presented at: 13th European Conference on Clinical Oncology and 24th Annual Meeting of the European Society for Therapeutic Radiology and Oncology. Lieu, Paris, France, 30 October–3 November 2005 (Abstract 642).
   Google Scholar
• Hohler T. Phase I/II study of cetuximab combined with 5-fluorouracil/leucovorin plus weekly oxaliplatin in first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer. Presented at: 30th European Society of Medical Oncology Congress. Vienna, Austria, 29 October–2 November 2004.
   Google Scholar
• Borner M, Mingrone W, Koeberle D et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer: a randomised Phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc. Am. Soc. Clin. Oncol.24, 18S (2006) (Abstract 3551).
   Google Scholar
• Colucci G, Giuliani F, Mattioli R et al. FOLFOX4 + cetuximab in untreated patients with advanced colorectal cancer. A Phase II study of the Gruppo Oncologico dell’Italia Meridionale (prot. GOIM 2402). Proc. Am. Soc. Clin. Oncol.24, S18 (2006) (Abstract 3559).
   Google Scholar
• Venook A, Niedzwiecki D, Hollis D et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic colorectal adenocarcinoma of the colon or rectum: CALGB 80203 preliminary results. Proc. Am. Soc. Clin. Oncol.24, 18S (2006) (Abstract 3509).
   Google Scholar
• Dakhil S, Cosgriff T, Headley D, Badarinath S, Boccia RV. Cetuximab +FOLFOX6 as first-line therapy for metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.24, S18 (2006) (Abstract 3557).
   Google Scholar
• Tabernero J, Cervantes A, Martinelli E et al. Optimal dose of cetuximab given every two weeks: a Phase I pharmacokinetic and pharmacodynamic study of weekly and every two weeks schedules in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.24, 18S (2006) (Abstract 3085).
   Google Scholar
• Malik I, Hecht JR, Patnaik A et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.23, S16 (2005) (Abstract 3520).
   Google Scholar
• van Cutsem E, Peeters M, Siena S et al. Panitumumab significantly improves progression free survival in patients with metastatic colorectal cancer. Presented at: 8th World Congress on Gastrointestinal Cancer. Barcelona, Spain, 28 June–2 July 2006.
   Google Scholar
• Vanhoefer U, Tewes M, Rojo F et al. Phase I study of the humanized anti-epidermal growth factor receptor monoclonal antibody EDM-72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol.22(1), 175–184 (2004).
   PubMed Web of Science ®Google Scholar
• Mackenzie MJ, Hirte HW, Glenwood G et al. A Phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest. New Drugs23(2), 165–170 (2005).
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, LaFleur B, Levy DE et al. Randomized Phase II trial of the clinical and biological effect of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J. Clin. Oncol.23(36), 9265–9274 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher GA, Kuo T, Cho CD et al. A Phase II study of gefitinib in combination with FOLFOX4 in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.22, 14S (2004) (Abstract 3514).
   Google Scholar
• Kindler HL, Friberg G, Skoog L, Wade-Oliver K, Vokes E. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am. J. Clin. Oncol.28(4), 340–344 (2005).
   PubMed Web of Science ®Google Scholar
• Wolpin BM, ClarkJW, Meyerhardt JA et al. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin. Colorectal Cancer6(3), 208–213 (2006).
   PubMed Web of Science ®Google Scholar
• Veronesse ML, Sun W, Giantonio B et al. A Phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br. J. Cancer92(10), 1846–1849 (2005).
   PubMed Web of Science ®Google Scholar
• Kuo T, Cho CD, Halsey J et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J. Clin. Oncol.23(24), 5613–5619 (2005).
   PubMed Web of Science ®Google Scholar
• Townsley CA, Major P, Siu LL et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br. J. Cancer94(8), 1136–1143 (2006).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Arnold D, Niederle N et al. Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohorts Phase II trial. Proc. Am. Soc. Clin. Oncol.23, S16 (2005) (Abstract 3575).
   Google Scholar
• Hanauske AR, Diaz-Rubio E, Cassidy J et al. Erlotinib HCI in combination with FOLFOX-4 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 789).
   Google Scholar
• Meyerhardt JA, Zhu AX, Enzinger PC et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastatic colorectal cancer. J. Clin. Oncol.24(12), 1892–1897 (2006).
   PubMed Web of Science ®Google Scholar
• Delord JP, Beale P, Van Cutsem E et al. A Phase Ib dose-escalation trial of erlotinib, capecitabine, and oxaliplatin in metastatic colorectal cancer patients. Proc. Am. Soc. Clin. Oncol.22, S14 (2004) (Abstract 3585).
   Google Scholar
• Spigel DR, Hainsworth JD, Burris HA et al. Phase II study of FOLFOX4, bevacizumab, and erlotinib as first-line therapy in patients with advanced colorectal cancer. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 26–28 January 2006 (Abstract 238).
   Google Scholar
• Meyerhardt JA, Stuart K, Zhu A et al. Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.24, S18 (2006) (Abstract 3545).
   Google Scholar
• Tejpar S, Van Cutsem E, Gamelin D et al. Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4), in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol.22, 14S (2004) (Abstract 3579).
   Google Scholar
• Casado E, Folprecht G, Paz-Ares L et al. A Phase I/IIA pharmacokinetic and serial skin and tumor pharmacodynamic study of the EGFR irreversible tyrosine kinase inhibitor EKB-569, in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI regimen) in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol.22, S14 (2004) (Abstract 3543).
   Google Scholar
• Baselga J, Schöffski P, Rojo F et al. A Phase I pharmacokinetic and molecular pharmacodynamic of the combination of two anti-EGFR therapies, the monoclonal antibody cetuximab, and the tyrosine kinase inhibitior gefitinib, in patients with advanced colorectal, head and neck, and non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol.24, S18 (2006) (Abstract 3006).
   Google Scholar
• Saltz L, Kies M, Abbruzzese JL et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignances. Proc. Am. Soc. Clin. Oncol.22, (2003) (Abstract 817).
   Google Scholar
• Van Cutsem E, Humblet Y, Gelderblom H et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19–21 January 2007 (Abstract 237).
   Google Scholar
• Hebbar N, Wacranier A, Desauw C et al. Lack of usefulness of epidermal growth factor receptor determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs17(7), 855–857 (2006).
   PubMed Web of Science ®Google Scholar
• Chung KI, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.23(9), 1803–1810 (2005).
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol.6(5), 257–258 (2005).
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Le Corre D et al. KRAS mutations status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res.66(8), 3992–3995 (2006).
   PubMed Web of Science ®Google Scholar
• Ciardello F, Bianco R, Damiano V et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res.6, 3739–3747 (2000).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Lenz H, Hochster S et al. Randomised Phase II study of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol.23, S16 (2005) (Abstract 3508).
   Google Scholar